In honour of Juvenile Arthritis Awareness Month in Canada, we have compiled a list of interviews from this year’s CRA Annual Scientific Meeting & AHPA Annual Meeting in Ottawa. The interviews below highlight models of care, advocacy, clinical practices, and different therapy options for juvenile arthritis. Continue reading
James Lowe is a New Zealand rugby union player and an official ambassador for Arthritis New Zealand. Lowe plays in the wing position for the Markos and Chiefs. In 2014, he played his first Super Rugby and contributed to the Chiefs 18-10 victory over the Crusaders in Christchurch. His aim is to play for the Kiwi World Cup squad in the near future.
Lowe was diagnosed with juvenile rheumatoid arthritis, also known as juvenile idiopathic arthritis (JIA), at the young age of 14. He takes prescribed medications and a weekly injection to control his arthritis. JIA strikes children under the age of 16 and affects an estimated one in 1000 children. It is one of the most common chronic diseases among children. To read about the different subtypes of juvenile idiopathic arthritis, please click here. Continue reading
A press release issued on June 9, 2016 by the European League Against Rheumatism Annual Congress highlighted a study that suggest depression is linked to disease activity and disability in adolescents with juvenile idiopathic arthritis. Below is a copy of the press release:
European League Against Rheumatism Annual Congress
London, United Kingdom, 8-11 June 2016
DEPRESSION LINKED TO DISEASE ACTIVITY AND DISABILITY IN ADOLESCENTS WITH ARTHRITIS
Study reinforces the importance of psychological assessment and support
London, United Kingdom, 9 June 2016: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) confirmed a clear association between depression symptom severity and the level of disease activity and disability in adolescent patients with juvenile inflammatory arthritis (JIA). These findings highlight the importance of psychological health assessment for adolescents with JIA and underline the need for psychological support to be fully integrated into their routine care.
BC PharmaCare is looking for your input on canakinumab for the treatment of systemic juvenile idiopathic arthritis (sJIA)
Canakinumab (Ilaris®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about canakinumab for the treatment of sJIA.
You can give input if you are a B.C. resident and have sJIA, a caregiver to someone with sJIA, or if your group represents people who live with sJIA.
The input is reviewed by the Drug Benefit Council, which then gives recommendations on whether a medication should be covered, and how, by BC PharmaCare. BC PharmaCare then makes a decision based on those recommendations and available resources. Policies and plans already in place also factor in the decision making process. Continue reading